Company news

Ligand Pharmaceuticals Incorporated news in 2022

Ligand Pharmaceuticals Incorporated's news releases, calls and decks from 2022, newest first.

View company

Ligand Provides Highlights from its Investor and Analyst Day Event

December 12, 2022

Ligand Pharmaceuticals Names Director Todd C. Davis as CEO

December 4, 2022

Ligand to Hold Investor and Analyst Day on December 13

November 15, 2022

Ligand Reports Third Quarter 2022 Financial Results

November 6, 2022

Ligand Distribution of OmniAb Complete and Business Combination Closed

October 31, 2022

Ligand Announces Completion of OmniAb Spin-Off

October 31, 2022

Ligand to Report Third Quarter Financial Results on November 7

October 25, 2022

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

October 25, 2022

Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2022

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

October 2, 2022

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

August 23, 2022

Ligand Reports Second Quarter 2022 Financial Results

August 7, 2022

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 31, 2022

Ligand to Report Second Quarter Financial Results on August 8

July 21, 2022

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

June 28, 2022

Ligand Reports First Quarter 2022 Financial Results

May 3, 2022

Ligand to Report First Quarter Financial Results on May 4

April 18, 2022

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

March 22, 2022

Ligand Reports Fourth Quarter and Full Year 2021 Financial Results

February 16, 2022

Ligand to Report Fourth Quarter Financial Results on February 17

February 8, 2022

Calls in 2022

Decks in 2022